Volpara gets FDA go-ahead on breast density assessment aid

Volpara Solutions has won FDA 510(k) clearance for software designed to help radiologists meet the BI-RADS Atlas fifth-edition requirement to provide an overall assessment of the volume of attenuating tissues in the breast.

A press release from the New Zealand-based company says the product line, Volpara Density Maps, helps point out the likelihood that a lesion may be obscured by especially dense tissue.

Volpara Density Maps present the 3D quantitative volumetric information created by the VolparaDensity algorithm in a 2D image that is available as an additional DICOM secondary capture image, according to the company.

Volpara further explains that the algorithm measures the compressed thickness and volume of dense tissue, which “enables the software to highlight specific parts of the breast tissue that are especially dense, including marking the densest 1-cm2 region of the image that might warrant closer inspection due to the masking risk.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.